Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Wednesday 24 February, 2021

Omega Diagnostics Gp

UK-RTC statement on AbC-19TM rapid antibody test

RNS Number : 1115Q
Omega Diagnostics Group PLC
24 February 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

UK-RTC statement on AbC-19TM rapid antibody test

 

Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine

AbC-19TM rapid antibody test was effective in demonstrating immune response following first dose vaccination

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes   the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, which presents new data relating to the performance of the AbC-19TM rapid antibody test when used as a companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine. The initial study performed at the University of Birmingham highlighted the effectiveness of the AbC-19TM rapid antibody test in demonstrating immune response following vaccination.

 

During the study t he AbC-19™ Rapid Test was used to test individuals who had been given a single dose of the Pfizer-BioNTech COVID-19 vaccine. In total 193 individuals who had received a COVID-19 vaccine were tested for the presence of IgG antibodies to the full trimeric spike using the AbC-19TM test. Of these individuals, a sub-set of 65 patients had been determined to have previously been infected with COVID-19, and 128 had no previous infection. The study also concluded that patients previously infected with COVID-19 showed a stronger immune response to the first dose of the Pfizer-BioNTech COVID-19 vaccine.

 

Following the study the statement from the UK-RTC said:

"The initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination. Should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings."

 

The UK-RTC press release is reproduced in full at the end of the statement and can be found here: 

https://www.abc19.com/

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadiagnostics.com

Colin King, Chief Executive 

via Walbrook PR

Kieron Harbinson, Group Finance Director




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

Press release from the UK-RTC (issued on 24 February 2021)

 

The UK-RTC, a consortium of UK diagnostic companies including Abingdon Health, CIGA Healthcare, BBI Solutions and Omega Diagnostics, presents new data examining the performance of the AbC-19TM rapid antibody test when used with 193 individuals that had received a single dose of the Pfizer-BioNTech COVID-19 vaccination. This study was performed at the University of Birmingham.

 

The sample population included a sub-set of 65 patients that had previously been infected with COVID-19, and 128 that had no previous infection. The highlights of the data/study are as follows:

 

· The AbC-19TM rapid antibody test was effective in demonstrating the immune response of patients to the first dose of the Pfizer-BioNTech COVID-19 vaccine,

 

· The study highlighted a differential immune response of two cohorts of patients: those previously infected with COVID-19 and those not infected;

 

· Patients previously infected with COVID-19 showed a stronger immune response to the first dose of the Pfizer-BioNTech COVID-19 vaccine;

 

The initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination Should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings.

 

The AbC-19™ Rapid Test was used to test samples from individuals who had been given a single dose of the Pfizer-BioNTech COVID-19 vaccine. In total 193 individuals who had received a COVID-19 vaccine were tested for the presence of IgG antibodies to the full trimeric spike using the AbC-19TM test.

 

Of the patients involved in the study, the AbC-19TM rapid test identified 181 (94%) as testing positive for the presence of IgG antibodies to COVID-19, with some samples from those with previous infection demonstrating a positive result as little as 1-4 days post vaccination. Using a cut-off of 13 days post-vaccination (which is the minimum recommendation for determining antibody status using the AbC-19TM rapid test) 137 out of 140 of samples, or 98% of patients, were identified as testing positive for the presence of IgG antibodies.

 

Using the WHO classification of the lateral flow device test line, results were classified as:

 

· 0 (negative)

· 1 (very weak but definitely reactive)

· 2 (medium to strong reactivity)

 

Of the 193 individuals examined, 128 (66%) patients were determined as not having a previous COVID-19 infection and thus naïve samples, with 65 (34%) patients identified as having a previous COVID-19 infection. 

 

When applying the above scoring to the samples taken 13 days after the single vaccination, 43.3% of the naïve samples scored medium to strong test line response with 53.8% showing a weaker response and 2.9% having a negative result. In contrast, those who had previously been infected with COVID-19 had a stronger response in 75% individuals, while 25% showed a weaker response with no negative results. It would be expected for the IgG anti-spike antibody levels to continue to rise with time and following a second vaccination.

 

Further studies are being performed to expand this data set and are expected to be available in the next few weeks.

 

About the UK-RTC

The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally. Led by Abingdon Health, it's members also include, BBI Solutions, CIGA Healthcare and Omega Diagnostics. The Abc-19TM is approved in Europe and the UK for professional use and is available for sale.

 

About the AbC-19™ Rapid Test 

The AbC-19™ Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in human capillary whole blood.  

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUMWPUPGPGW

a d v e r t i s e m e n t